Celonic Group News and Resources

Celonic Group has announced the integration of Merck’s Breez micro-bioreactor platform into its process development workflows. The Swiss-based CDMO aims to enhance its capabilities in monoclonal antibody (mAb) manufacturing by leveraging Breez for scalable perfusion-based bioprocessing. The Breez 2 mL micro-bioreactor

Celonic Group, a Swiss-based Quality Biologics Contract Development and Manufacturing Organization (CDMO), has inaugurated a new Biologics Development Center and Pilot Plant in Basel, Switzerland. This expansion aims to support pharmaceutical companies in developing and optimizing processes with advanced bioprocessing